Allergan targets liver disease drugs with Tobira acquisition

Botox-maker Allergan is bulking up its drug pipeline with two acquisitions announced Tuesday, both of which target liver disease.

Allergan PLC said it's acquiring Tobira Therapeutics Inc. and two potential liver disease treatments in a deal that could be worth almost $1.7 billion.

Tobira is testing two treatments for non-alcoholic steatohepatitis, or NASH, a disease that triggers inflammation that can lead to cirrhosis, cancer and eventual liver failure.

Allergan targets liver disease drugs with Tobira acquisition